Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations

American Journal of Cardiology

Volumn 91, Issue 9 SUPPL. 1, 2003, Pages 18-40

  Klein, Liviu ^a   O'Connor, Christopher M ^b   Gattis, Wendy A ^b   Zampino, Manuela ^c   De Luca, Leonardo ^d   Vitarelli, Antonio ^c   Fedele, Francesco ^d   Gheorghiade, Mihai ^e  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CALCIUM ANTAGONIST; CAPTOPRIL; CARVEDILOL; CHLOROTHIAZIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ETACRYNIC ACID; FOSINOPRIL; FUROSEMIDE; HYDRAZINE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; METOLAZONE; METOPROLOL; MOXONIDINE; RAMIPRIL; SPIRONOLACTONE; TRANDALOPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

AFRICA; ANGIONEUROTIC EDEMA; CARDIOVASCULAR RISK; CONFERENCE PAPER; COUGHING; DEFIBRILLATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFECT; FAMILY HISTORY; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; PRIORITY JOURNAL; SUBSTITUTION THERAPY; SUDDEN DEATH; SYMPTOM; SYSTOLIC BLOOD PRESSURE; WESTERN HEMISPHERE;

EID: 0037728841     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03336-2     Document Type: Conference Paper

References (216)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.
2. Miller L.W., Missov E.D. Epidemiology of heart failure. Cardiol Clin. 19:2001;547-555.
3. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., Murabito J.M., Vasan R.S. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 347:2002;1397-1402.
4. Zannad F., Briancon S., Juilliere Y. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure the EPICAL Study . J Am Coll Cardiol. 33:1999;734-742.
5. Haldeman G.A., Croft J.B., Giles W.H., Rashidee A. Hospitalization of patients with heart failure National Hospital Discharge Survey, 1985 to 1995 . Am Heart J. 137:1999;352-360.
6. O'Connell J.B., Bristow M.R. Economic impact of heart failure in the United States time for a different approach . J Heart Lung Transplant. 13:1994;S107-S112.
7. Malek M. Health economics of heart failure. Heart. 82:1999;IV11-IV13.
8. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. 2001. Available at: http://www.acc.org. Accessed February 22, 2003.
9. Gheorghiade M., Gattis W.A., O'Connor C.M. Treatment gaps in the pharmacological management of heart failure. Rev Cardiovasc Med. 3:2002;S11-S19.
10. Felker G.M., O'Connor C.M. Inotropic therapy for heart failure an evidence-based approach . Am Heart J. 142:2001;393-401.
11. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States a manifestation of coronary artery disease . Circulation. 97:1999;282-289.
12. Bart B.A., Shaw L.K., McCants C.B., Fortin D.F., Lee K.L., Califf R.M., O'Connor C.M. Clinical determinants of mortality in patients with angiographically proven ischemic and non-ischemic cardiomyopathy. J Am Coll Cardiol. 30:1997;1002-1008.
13. Mathew J., Davidson S., Narra L., Hafeez T., Garg R. Etiology and characteristics of heart failure in blacks. Am J Cardiol. 78:1996;1447-1450.
14. Yancy C.W. Heart failure in African Americans a cardiovascular enigma . J Card Fail. 6:2000;183-186.
15. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 33:1999;1948-1955.
16. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., Redfield M.M. Congestive heart failure in the community a study of all incident cases in Olmsted County, Minnesota, in 1991 . Circulation. 98:1998;2282-2289.
17. Kitzman D.W., Gardin J.M., Gottdiener J.S., Arnold A., Boineau R., Aurigemma G., Marino E.K., Lyles M., Cushman M., Enright P.L. Importance of heart failure with preserved systolic function in patients ≥65 years of age Cardiovascular Health Study . Am J Cardiol. 87:2001;413-419.
18. Choudhury L., Gheorghiade M., Bonow R.O. Coronary artery disease in patients with heart failure and preserved systolic function. Am J Cardiol. 89:2002;719-722.
19. Bourassa M.G., Gurne O., Bangdiwala S.I., Ghali J.K., Young J.B., Rousseau M., Johnstone D.E., Yusuf S. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 22:(suppl A):1993;14A-19A.
20. Gheorghiade M., Cody R.J., Francis G.S., McKenna W.J., Young J.B., Bonow R.O. Current medical therapy for advanced heart failure. Am Heart J. 135:1998;S231-S248.
21. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 88:1993;107-115.
22. Stevenson W.G., Stevenson L.W., Middlekauff H.R., Saxon L.A. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 88:1993;2953-2961.
23. Braunwald E., Bristow M.R. Congestive heart failure fifty years of progress . Circulation. 102:2002;IV14-IV23.
24. Mann D. Mechanisms and models in heart failure a combinatorial approach . Circulation. 100:1999;999-1008.
25. Francis G.S. Pathophysiology of chronic heart failure. Am J Med. 110:2001;37S-46S.
26. Ambrosio G., Betocchi S., Pace L., Losi M.A., Perrone-Filardi P., Soricelli A., Piscione F., Taube J., Squame F., Salvatore M., Weiss J.L., Chiariello M. Prolonged impairment of regional contractile function after resolution of exercise induced angina evidence of myocardial stunning in patients with coronary artery disease . Circulation. 94:1996;2455-2464.
27. Bonow R.O. The hibernating myocardium implications for management of congestive heart failure . Am J Cardiol. 75:(suppl):1995;17A-25A.
28. Elsasser A., Schlepper M., Klovekorn W.P., Cai W., Zimmermann R., Muller K.D., Strasser R., Kostin S., Gagel C., Munkel B., Schaper W., Schaper J. Hibernating myocardium an incomplete adaptation to ischemia . Circulation. 92:1995;2920-2931.
29. Sabbah H.N. Apoptotic cell death in heart failure. Cardiovasc Res. 45:2000;704-712.
30. Taneja T., Gheorghiade M., Bonow R.O. Heart failure in the new millennium emerging concepts in its pathophysiology . Advances in Rehabilitation. 10:2000;61-76.
31. Paulus W.J., Vantrimpont P.J., Shah A.M. Paracrine coronary endothelial control of left ventricular function in humans. Circulation. 92:1995;2119-2126.
32. Colucci W.S. Myocardial endothelin does it play a role in myocardial failure? Circulation. 93:1996;1069-1072.
33. Deedwania P. Endothelin, the bad actor in the play a marker or mediator of cardiovascular disease . J Am Coll Cardiol. 33:1999;939-942.
34. Murray D.R., Prabhu S.D., Chandrasekar B. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation. 101:2000;2338-2341.
35. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 223:1990;236-241.
36. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B., Mann D.L. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
37. Bozkurt B., Kribbs S.B., Clubb F.J., Michael L.H., Didenko V.V., Hornsby P.J., Seta Y., Oral H., Spinale F.G., Mann D.L. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
38. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 334:1996;1717-1725.
39. Weber K.T. Extracellular matrix remodeling in heart failure. Circulation. 96:1997;4065-4082.
40. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A., Pozzi M., Morganti A., Carugo S., Mancia G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 96:1997;1173-1179.
41. Gilbert E.M., Sandoval A., Larrabee P., Renlund D.G., O'Connell J.B., Bristow M.R. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation. 88:1993;472-480.
42. MacFadyen R.J., Barr C.S., Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability, and reduces early morning rise in heart failure patients. Cardiovasc Res. 35:1997;30-34.
43. Francis G.S. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J. 118:1989;642-648.
44. Rahman S.N., Kim G.E., Mathew A.S., Goldberg C.A., Allgren R., Schrier R.W., Conger J.D. Effects of atrial natriuretic peptide in clinical acute heart failure. Kidney Int. 45:1994;1731-1738.
45. Gerdes A.M., Kellerman S.E., Moore J.A., Muffly K.E., Clark L.C., Reaves P.Y., Malec K.B., McKeown P.P., Schocken D.D. Structural remodeling of cardiac myocytes from patients with chronic ischemic heart disease. Circulation. 86:1992;426-430.
46. Kono T., Sabbah H.N., Stein P.D., Brymer J.F., Khaja F. Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 68:1991;355-359.
47. Nass O., Rosman H., Al-Khaled N., Shimoyama H., Alam M., Sabbah H.N., Goldstein S. Relation of left ventricular chamber shape in patients with low (≤40%) ejection fraction to severity of functional mitral regurgitation. Am J Cardiol. 76:1995;402-404.
48. Edwards N.C., Sinusas A.J., Bergin J.D., Watson D.D., Ruiz M., Beller G.A. Influence of subendocardial ischemia on transmural myocardial function. Am J Physiol. 262:1992;H568-H576.
49. Unverferth D.V., Magorien R.D., Lewis R.P., Leier C.V. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J. 105:1983;176-179.
50. Leiden J.M. The genetics of dilated cardiomyopathy emerging clues to the puzzle . N Engl J Med. 337:1997;1080-1081.
51. Olson T.M., Michels V.V., Thibodeau S.N., Tai Y.S., Keating M.T. Actin mutations in dilated cardiomyopathy a heritable form of heart failure . Science. 280:1998;750-752.
52. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 102:1998;1534-1539.
53. 2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 347:2002;1135-1142.
54. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H.B. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167.
55. Cheitlin M.D., Alpert J.S., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davidson T.W., Davis J.L., Douglas P.S., Gillam L.D., et al. ACC/AHA guidelines for the clinical application of echocardiography executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography) . J Am Coll Cardiol. 29:1997;862-879.
56. Bristow M.R., Port J.D., Kelly R.A. Inhibitors of the renin-angiotensin-aldosterone system. Braunwald E., Libby P., Zipes D.D., Zipes D.P. Heart Disease A Textbook of Cardiovascular Medicine . 2001;582-583 WB Saunders, Philadelphia.
57. Bastien N.R., Juneau A.V., Ouellette J., Lambert C. Chronic AT1 receptor blockade and angiotensin-converting enzyme inhibition in (HF 146) cardiomyopathic hamsters effects on cardiac hypertrophy and survival . Cardiovasc Res. 43:1999;77-85.
58. Brown N.J., Ryder D., Gainer J.V., Morrow J.D., Nadeau J. Differential effects of angiotensin-converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther. 279:1996;703-712.
59. Sharpe D.N., Murphy J., Coxon R., Hannan S.F. Enalapril in patients with chronic heart failure a placebo-controlled, randomized, double-blind study . Circulation. 70:1984;271-278.
60. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 259:1988;539-544.
61. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 2:1983;755-763.
62. LeJemtel T.H., Keung E., Frishman W.H., Ribner H.S. Hemodynamic effects of captopril in patients with severe heart failure. Am J Cardiol. 49:1982;1484-1488.
63. DiCarlo L., Chatterjee K., Parmley W.W., Swedberg K., Atherton B., Curran D., Cucci M. Enalapril a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations . J Am Coll Cardiol. 2:1983;865-871.
64. Awan N.A., Amsterdam E.A., Hermanovich J., Bommer W.J., Needham K.E., Mason D.T. Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of chronic congestive heart failure. Am Heart J. 103:1982;474-479.
65. Konstam M.A., Rousseau M.F., Kronenberg M.W., Udelson J.E., Melin J., Stewart D., Dolan N., Edens T.R., Ahn S., Kinan D. Effects of the angiotensin-converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation. 88:1993;2277-2283.
66. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study . N Engl J Med. 316:1987;1429-1435.
67. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
68. Jong P, Yusuf S, XSOLVD Investigators. Extended follow-up of the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials. Presented at the European Society of Cardiology Meeting; August 31-September 4, 2002; Berlin, Germany.
69. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
70. Yusuf S., Pepine C.J., Garces C., Pouler H., Salem D., Kostis J., Benedict C., Rousseau M., Bourassa M., Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
71. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 327:1992;669-677.
72. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
73. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators . N Engl J Med. 332:1995;80-85.
74. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D.S., Auclert L., Pauly N.C. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
75. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., Ryden L., Thygesen K., Uretsky B.F. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 100:1999;2312-2318.
76. Clinical outcome with enalapril in symptomatic chronic heart failure a dose comparison . Eur Heart J. 19:1998;481-489.
77. Exner D.V., Dries D.L., Domanski M.J., Cohn J.N. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 344:2001;1351-1357.
78. Dries D.L., Strong M.H., Cooper R.S., Drazner M.H. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 40:2002;311-317.
79. 1-adrenergic receptor subtypes mediating vasoconstriction in rabbit cutaneous resistance arteries. Br J Pharmacol. 122:1997;825-832.
80. 1B-Adrenergic receptors mediate renal tubular sodium and water reabsorption in the rat. Br J Pharmacol. 111:1994;819-824.
81. Hasenfuss G., Holubarsch C., Blanchard E.M., Mulieri L.A., Alpert N.R., Just H. Influence of isoproterenol on myocardial energetics experimental and clinical investigations . Basic Res Cardiol. 84:1989;S147-S155.
82. 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem. 268:1993;15374-15380.
83. Communal C., Singh K., Pimentel D.R., Colucci W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation. 98:1998;1329-1334.
84. 2-adrenoceptors mediate catecholamine evoked arrhythmias in isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol. 348:1993;536-540.
85. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., Gilbert E.M., Johnson M.R., Goss F.G., Hjalmarson A. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
86. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy the randomized evaluation of strategies for left ventricular dysfunction pilot study . Circulation. 101:2000;378-384.
87. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., Wikstrand J., El Allaf D., Vitovec J., Aldershvile J. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) . JAMA. 283:2000;1295-1302.
88. A randomized trial of β-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
89. Colucci W.S., Packer M., Bristow M.R., Gilbert E.M., Cohn J.N., Fowler M.B., Krueger S.K., Hershberger R., Uretsky B.F., Bowers J.A., et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
90. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the PRECISE Trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise . Circulation. 94:1996;2793-2799.
91. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
92. Cohn J.N., Fowler M.B., Bristow M.R., Colucci W.S., Gilbert E.M., Kinhal V., Krueger S.K., LeJemtel T., Narahara K.A., Packer M., et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 3:1997;173-179.
93. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
94. Goldstein S., Fagerberg B., Hjalmarson A., Kjekshus J., Waagstein F., Wedel H., Wikstrand J. Metoprolol controlled/extended release in patients with severe heart failure analysis of the experience in the MERIT-HF study . J Am Coll Cardiol. 38:2001;932-938.
95. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II) a randomised trial . Lancet. 353:1999;9-13.
96. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
97. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
98. Poole-Wilson P.A., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., Metra M., Remme W.J., Swedberg K., Torp-Pedersen C. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure COMET . Eur J Heart Fail. 4:2002;321-329.
99. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:2001;1659-1667.
100. Coats A.J.S. Heart failure 99 the MOXCON story . Int J Cardiol. 71:1999;109-111.
101. Yancy C.W., Fowler M.B., Colucci W.S., Gilbert E.M., Bristow M.R., Cohn J.N., Lukas M.A., Young S.T., Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 344:2001;1358-1365.
102. 1-adrenergic receptor polymorphisms analysis of c145AG and c1165GC . Hum Mutat. 14:1999;271-275.
103. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction the CAPRICORN randomised trial . Lancet. 357:2001;1385-1390.
104. Gheorghiade M, Colluci WS, Swedberg K. β-Blockers in chronic heart failure. Circulation. In press.
105. Wikstrand J., Hjalmarson A., Waagstein F., Fagerberg B., Goldstein S., Kjekshus J., Wedel H. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) . J Am Coll Cardiol. 40:2002;491-498.
106. Gheorghiade M, Gattis WA, Lukas MA, O'Connor CM. Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. Am Heart J 2003;145(suppl):S60-S61.
107. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., Dei Cas L. Differential effects of β-blockers in patients with heart failure a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol . Circulation. 102:2000;546-551.
108. Jacob S., Rett K., Wicklmayr M., Agrawal B., Augustin H.J., Dietze G.J. Differential effect of chronic treatment with two β-blocking agents on insulin sensitivity the carvedilol-metoprolol study . J Hypertens. 14:1996;489-494.
109. Packer M. Current role of β-adrenergic blockers in the management of chronic heart failure. Am J Med. 110:2001;81S-94S.
110. Struthers A.D. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol. 47:1999;479-482.
111. Jorde U.P., Vittorio T., Katz S.D., Colombo P.C., Latif F., LeJemtel T.H. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 106:2002;1055-1057.
112. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 2:1996;47-54.
113. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 102:2000;2700-2706.
114. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341:1999;709-717.
115. Pitt B., Remme W., Zannad F.J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348:2003;1309-1321.
116. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 103:2001;904-912.
117. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., Deedwania P.C., Ney D.E., Snavely D.B., Chang P.I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752.
118. Pitt S., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm J.A., Konstam M.A., Riegger G., Klinger G.H., Neaton J., Sharma D., Thiyagarajan B. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure the losartan heart failure survival study, ELITE II . Lancet. 355:2000;1582-1587.
119. Cohn J.N., Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675.
120. Maggioni A.P., Anand I., Gottlieb S.O., Latini R., Tognoni G., Cohn J.N. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 8:2002;1414-1421.
121. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction the OPTIMAAL randomised trial . Lancet. 360:2002;752-760.
122. Pfeffer M., McMurray J., Leizorovicz A., Maggioni A., Rouleau J., Van De Werf F., Henis M., Neuhart E., Gallo P., Edwards S., et al. Valsartan in acute myocardial infarction trial (VALIANT) rationale and design . Am Heart J. 140:2000;727-734.
123. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol . Lancet. 359:2002;995-1003.
124. Calderone A., Thaik C.M., Takahashi N., Chang D.L.F., Colucci W.S. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 101:1998;812-818.
125. Jugdutt B.I., Khan M.I. Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. Circulation. 89:1994;2297-2307.
126. Keith M., Geranmayegan A., Sole M.J., Kurian R., Robinson A., Omran A.S., Jeejeebhoy K.N. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 31:1998;1352-1356.
127. Bauer J.A., Fung H.L. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 84:1991;35-39.
128. Leier C.V., Huss P., Magorien R.D., Unverfderth D.V. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation. 67:1983;817-822.
129. Elkayam U., Roth A., Kumar A., Kulick D., McIntosh N., McKay C.R., Rahimtoola S.H. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. Am J Cardiol. 60:1987;1106-1111.
130. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., Flohr K.H. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
131. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W.B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
132. Roden R.L. Cardiovascular news cardiovascular and renal advisory panel of the United States Food and Drug Administration considers four drugs . Circulation. 95:1997;2335-2337.
133. Carson P., Ziesche S., Johnson G., Cohn J.N. Racial differences in response to therapy for heart failure analysis of the vasodilator-heart failure trials . J Card Fail. 5:1999;178-187.
134. Franciosa J.A., Taylor A.L., Cohn J.N., Yancy C.W., Ziesche S., Olukotun A., Ofili E., Ferdinand K., Loscalzo J., Worcel M. African-American Heart Failure Trial (A-HeFT) rationale, design, and methodology . J Card Fail. 8:2002;128-135.
135. + activated ATPase . Naunyn Schmiedebergs Arch Pharmacol. 277:1973;151-162.
136. Gheorghiade M., Ferguson D. Digoxin a neurohormonal modulator in heart failure? Circulation. 84:1991;2181-2186.
137. + ATPase the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure . Cardiovasc Res. 55:2002;710-713.
138. Eichhorn E., Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 44:2002;251-266.
139. Tauke J., Goldstein S., Gheorghiade M. Digoxin for chronic heart failure a review of the randomized controlled trials with special attention to the PROVED and RADIANCE trials . Prog Cardiovasc Dis. 37:1994;49-58.
140. Packer M., Gheorghiade M., Young J.B., Costantini P.J., Adams K.F., Cody R.J., Smith L.K., Van Voorhees L., Gourley L.A., Jolly M.K. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med. 329:1993;1-7.
141. Uretsky B.F., Young J.B., Shahidi F.E., Yellen L.G., Harrison M.C., Jolly M.K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure results of the PROVED Trial . J Am Coll Cardiol. 22:1993;955-962.
142. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
143. Gheorghiade M., Pitt B. Digitalis Investigation Group (DIG) trial a stimulus for further research . Am Heart J. 134:1997;3-12.
144. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-878.
145. Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 347:2002;1403-1411.
146. Eichhorn E., Gheorghiade M. Digoxin new perspective on an old drug . N Engl J Med. 347:2002;1394-1395.
147. Adams K.F. Jr, Gheorghiade M., Uretsky B.F., Patterson J.H., Schwartz T.A., Young J.B. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 39:2002;946-953.
148. Brater D.C. Pharmacology of diuretics. Am J Med Sci. 319:2000;38-50.
149. Wilson J.R., Reichek N., Dunkman W.B., Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 70:1981;234-239.
150. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure clinical and neuroendocrine effects of introducing diuretics . Br Heart J. 57:1987;17-22.
151. Patterson J.H., Adams K.F. Jr, Applefeld M.M., Corder C.N., Masse B.R. Oral torsemide in patients with chronic congestive heart failure effects on body weight, edema, and electrolyte excretion: Torsemide Investigators Group . Pharmacotherapy. 14:1994;514-521.
152. Hensen J., Abraham W.T., Durr J., Schrier R.W. Aldosterone in congestive heart failure patients analysis of determinants and role in sodium retention . Am J Nephrol. 11:1991;441-446.
153. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 100:1999;1311-1315.
154. Cosin J., Diez J. Torsemide in chronic heart failure results of the TORIC study . Eur J Heart Fail. 4:2002;507-513.
155. Murray M.D., Deer M.M., Ferguson J.A., Dexter P.R., Bennett S.J., Perkins S.M., Smith F.E., Lane K.A., Adams L.D., Tierney W.M., Brater D.C. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 111:2001;513-520.
156. Elkayam U., Amin J., Mehra A., Vasquez J., Weber L., Rahimtoola S.H. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 82:1990;1954-1961.
157. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction the Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group . Circulation. 83:1991;52-60.
158. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberg G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
159. Packer M, on behalf of PRAISE II Investigators. Preliminary results of the Second Prospective Randomized Amlodipine Survival Evaluation. Presented at the 49th Annual Scientific Session of the American College of Cardiology, March 12-16, 2000; Anaheim, California.
160. Cohn J.N., Ziesche S., Smith R., Anand I., Dunkman W.B., Loeb H., Cintron G., Boden W., Baruch L., Rochin P., Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril V-HeFT III . Circulation. 96:1997;856-863.
161. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
162. Uretsky B.F., Jessup M., Konstam M.A., Dec G.W., Leier C.V., Benotti J., Murali S., Herrmann H.C., Sandberg J.A. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure lack of benefit compared with placebo. Enoximone Multicenter Trial Group . Circulation. 82:1990;774-780.
163. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., Di Bianco R., Zeldis S.M., Hendrix G.H., Bommer W.J., Elkayam U., Kukin M.L. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
164. Van Veldhuisen D.J., Man In't Veld A.J., Dunselman P.H.J.M., Lok D.J.A., Dohmen H.J.M., Poortermans J.C., Withagen A.J.A.M., Pasteuning W.H., Brouwer J., Lie K.I. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure results of the Dutch Ibopamine Multicenter Trial (DIMT) . J Am Coll Cardiol. 22:1993;1564-1573.
165. Dohmen H.J., Dunselman P.H., Poole-Wilson P.A. Comparison of captopril and ibopamine in mild to moderate heart failure. Heart. 78:1997;285-290.
166. Hampton J.R., van Veldhuisen D.J., Kleber F.X., Cowley A.J., Ardia A., Block P., Cortina A., Cserhalmi L., Follath F., Jensen G., et al. Randomised study of effect of ibopamine on survival in patients with advanced heart failure. Lancet. 349:1997;971-977.
167. Effect of pimobendan on exercise capacity in patients with heart failure main results from the Pimobendan in Congestive Heart Failure (PICO) trial . Heart. 76:1996;223-231.
168. Feldman A.M., Bristow M.R., Parmley W.W., Carson P.E., Pepine C.J., Gilbert E.M., Strobeck J.E., Hendrix G.H., Powers E.R., Bain R.P., White B.G. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
169. Cohn J.N., Goldstein S.O., Greenberg B.H., Lorell B.H., Bourge R.C., Jaski B.E., Gottlieb S.O., McGrew F. 3rd, DeMets D.L., White B.G. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure Vesnarinone Trial Investigators . N Engl J Med. 339:1998;1810-1816.
170. Dies F., Krell M.J., Whitlow P. Intermittent dobutamine in ambulatory outpatients with chronic heart failure. Circulation. 74:1986;II-38.
171. Oliva F., Latini R., Politi A., Staszewsky L., Maggioni A.P., Nicolis E., Mauri F. Intermittent 6-month low-dose dobutamine infusion in severe heart failure DICE Multicenter Trial . Am Heart J. 138:1999;247-253.
172. Elis A., Bental T., Kimchi O., Ravid M., Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure a randomized, double-blind, placebo-controlled study . Clin Pharmacol Ther. 63:1998;682-685.
173. Silver M.A., Horton D.P., Ghali J.K., Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with decompensated heart failure. J Am Coll Cardiol. 39:2002;798-803.
174. Cuffe S.M., Califf R.M., Adams K.F., Benza R., Bourge R., Colluci W.S., Massie B.M., O'Connor C.M., Pina I., Quigg R., Silver M.A., Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA. 287:2002;1541-1547.
175. Packer M., Rouleau J., Swedberg K., Pitt B., Fisher L., Klepper M. Effect of flosequinan on survival in chronic heart failure preliminary results of the PROFILE study [abstract] . Circulation. 88:1993;I-501.
176. Packer M., Narahara K.A., Elkayam U., Sullivan J.M., Pearle D.L., Massie B.M., Creager M.A. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure Principal Investigators of the REFLECT Study . J Am Coll Cardiol. 22:1993;65-72.
177. Sueta C.A., Gheorghiade M., Adams K.F., Bourge R.C., Murali S., Uretsky B.F., Pritzker M.R., McGoon M.D., Butman S.M., Grossman S.H., et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol. 75:(suppl):1995;34A-43A.
178. Califf R.M., Adams K.F., McKenna W.J., Gheorghiade M., Uretsky B.F., McNulty S.E., Darius H., Schulman K., Zannad F., Handberg-Thurmond E., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure the Flolan International Randomized Survival Trial (FIRST) . Am Heart J. 134:1997;44-54.
179. Francis G.S. Development of arrhythmias in the patient with congestive heart failure pathophysiology, prevalence, and prognosis . Am J Cardiol. 57:1986;3-7.
180. Chakko C.S., Gheorghiade M. Ventricular arrhythmias in severe heart failure incidence, significance, and effectiveness of antiarrhythmic therapy . Am Heart J. 109:1985;497-504.
181. Podrid P.J., Lampert S., Graboys T.B., Blatt C.M., Lown B. Aggravation of arrhythmia by antiarrhythmic drugs incidence and predictors . Am J Cardiol. 59:1987;38-44.
182. Echt D.S., Liebson P.R., Mitchell B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., Huther M.L., Richardson D.W. Mortality and morbidity in patients receiving encainide, flecainide, or placebo the Cardiac Arrhythmia Suppression Trial . N Engl J Med. 324:1991;781-788.
183. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
184. Doval H.C., Nul D.R., Grancelli H.O., Perrone S., Bortman G.R., Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
185. Singh S.N., Fletcher R.D., Fisher S.G., Singh B.N., Lewis H.D., Deedwania P.C., Massie B.M., Colling C., Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
186. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-674.
187. Waldo A.L., Camm A.J., De Ruyter H., Friedman P.L., Mac Neil D.J., Pauls J.F., Pitt B., Pratt C.M., Schwartz P.J., Veltri E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 348:1996;7-12.
188. Fuster V., Gersh B.J., Giuliani E.R., Tajik A.J., Brandenburg R.O., Frye R.L. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 47:1981;525-531.
189. Jafri S.M. Hypercoagulability in heart failure. Semin Thromb Hemost. 23:1997;543-545.
190. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN, V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87:VI94-VI101.
191. Cioffi G., Pozzoli M., Forni G., Franchini M., Opasich C., Cobelli F., Tavazzi L. Systemic thromboembolism in chronic heart failure a prospective study in 406 patients . Eur Heart J. 17:1996;1381-1389.
192. Shivkumar K., Jafri S.M., Gheorghiade M. Antithrombotic therapy in atrial fibrillation a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial . Prog Cardiovasc Dis. 38:1996;337-342.
193. Rademaker M.T., Charles C.J., Espiner E.A., Nicholls M.G., Richards A.M., Kosoglou T. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure role of natriuretic peptides and angiotensin II . J Cardiovasc Pharmacol. 31:1998;116-125.
194. Rouleau J.L., Pfeffer M.A., Stewart D.J., Isaac D., Sestier F., Kerut E.K., Porter C.B., Proulx G., Qian C., Block A.J. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure IMPRESS randomised trial . Lancet. 356:2000;615-620.
195. Packer M., Califf R.M., Konstam M.A., Krum H., McMurray J.J., Rouleau J.L., Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) . Circulation. 106:2002;920-926.
196. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the Studies of Left Ventricular Dysfunction (SOLVD) . J Am Coll Cardiol. 27:1996;1201-1206.
197. Franco F., Thomas G.D., Giroir B., Bryant D., Bullock M.C., Chwialkowski M.C., Victor R.G., Peshock R.M. Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-α Circulation. 99:1999;448-454.
198. Yue P., Massie B.M., Simpson P.C., Long C.S. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol. 275:1998;H250-H258.
199. Herrera-Garza E., Stetson S., Cubillos-Garzon A., Vooletich M., Farmer J.A., Torre-Amione G. Tumor necrosis factor-α a mediator of disease progression in the failing human heart . Chest. 115:1999;1170-1174.
200. Bozkurt B., Torre-Amione G., Warren M.S., Whitmore J., Soran O.Z., Feldman A.M., Mann D.L. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 103:2001;1044-1047.
201. Mann D, RENEWAL Investigators. Effects of etanercept on the morbidity and mortality in patients with chronic heart failure: results of the Randomized Etanercept World-Wide Evaluation (RENEWAL) Study. Presented at the Heart Failure Update Meeting; June 8-11, 2002; Oslo, Norway.
202. Packer M, ATTACH Investigators. Effects of anti-TNF-α therapy against chronic heart failure. Presented at the Heart Failure Update Meeting, June 8-11, 2002; Oslo, Norway.
203. Kelly J.J., Whitworth J.A. Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol. 26:1999;158-161.
204. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., Morton J.J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
205. Pousset F., Isnard R., Lechat P., Kalotka H., Carayon A., Maistret G., Escolano S., Thomas D., Komajda M. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 18:1997;254-258.
206. Abraham WT, ENCOR Investigators. Effects of enrasentan, a non-selective endothelin receptor antagonist, in class II-III heart failure: results of the ENCOR Trial. Presented at the 50th Annual Scientific Session of the American College of Cardiology, March 18-21, 2001; Orlando, Florida.
207. Packer M., Caspi A., Charlon V., et al. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure results of the REACH-1 trial [abstract] . Circulation. 98:1998;I-3.
208. Packer M, ENABLE Investigators. Effects of endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure: results of the ENABLE 1 and 2 programs. Presented at the 51st Annual Scientific Session of the American College of Cardiology; March 17-20, 2002; Atlanta, Georgia.
209. O'Connor C.M., Gattis W.A., Adams K.F., Shah M.R., Kobrin I., Frey A., Gheorghiade M. Tezosentan in patients with acute heart failure and acute coronary syndromes design of the Randomized Intravenous Tezosentan Study (RITZ-4) . Am Heart J. 144:2002;583-588.
210. Goldsmith S.R. Vasopressin a therapeutic target in congestive heart failure? J Card Fail. 5:1999;347-356.
211. Walker B.R., Childs M.E., Adams E.M. Direct cardiac effects of vasopressin role of V1- and V1-vasopressinergic receptors . Am J Physiol. 255:1988;H261-H265.
212. Schrier R.W., Berl T., Anderson R.J. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 236:1979;F321-F332.
213. Udelson J.E., Smith W.B., Hendrix G.H., Painchaud C.A., Ghazzi M., Thomas I., Ghali J.K., Selaru P., Chanoine F., Pressler M.L., Konstam M.A. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 104:2001;2417-2423.
214. Gheorghiade M, Niazi I, Ouyang J, Czerwlec F, Kambayashi JI, Orlandi C. Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: a randomized, double-blind trial [abstract]. Circulation 2000;102:II-592.
215. Gheorghiade M, Konstam MA, Udelson JE, Ouyang J, Orlandi C. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients [abstract]. Circulation 2000;102:II-438.
216. Gheorghiade M, Gattis WA, Barbagelata A, Adams K, Orlandi C, O'Connor CM, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003;145:S51-S54.